Testosterone Petition From Public Citizen Eyes Industry Bias In Risk Findings
This article was originally published in The Pink Sheet Daily
Seeking immediate relabeling of the products, advocacy group notes a meta-analysis found different CV risk depending on who funded the studies analyzed.
You may also be interested in...
Sponsored plotline for General Hospital was careful to avoid irking US FDA; agency withdrew its guidance on disease awareness campaigns in 2015, but its influence appears to be continuing, according to a former official.
Without predictive factors to determine who is likely to get a severe post-injection reaction, FDA advisory committees say Endo’s proposed REMS for its long-acting testosterone is unlikely to allay safety concerns.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.